Survival of de novo and secondary acute promyelocytic leukemia: a propensity-matched analysis of the SEER database

References

• Detourmignies L, Castaigne S, Stoppa AM, et al. Therapy-related acute promyelocytic leukemia: a report on 16 cases. J Clin Oncol 1992;10:1430–1435.
   PubMed Web of Science ®Google Scholar
• Andersen MK, Larson RA, Mauritzson N, et al. Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002;33: 395–400.
   PubMed Web of Science ®Google Scholar
• Beaumont M, Sanz M, Carli PM, et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003;21:2123–2137.
   PubMed Web of Science ®Google Scholar
• Pulsoni A, Pagano L, Lo Coco F, et al. Clinicobiological features and outcome of acute promyelocytic leukemia occurring as a second tumor: the GIMEMA experience. Blood 2002;100:1972–1976.
   PubMed Web of Science ®Google Scholar
• Duffield AS, Aoki J, Levis M, et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol 2012;137:395–402.
   PubMed Web of Science ®Google Scholar
• Andersen MK, Johansson B, Larsen SO, et al. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica 1998;83:483–488.
   Google Scholar
• Rashidi A, Fisher SI. Therapy-related acute promyelocytic leukemia: a systematic review. Med Oncol 2013;30:625.
   PubMed Web of Science ®Google Scholar
• Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529–1538.
   PubMed Web of Science ®Google Scholar
• Hasan SK, Ottone T, Schlenk RF, et al. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci. Genes Chromosomes Cancer 2010;49:726–732.
   PubMed Web of Science ®Google Scholar
• Mays AN, Osheroff N, Xiao Y, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010;115:326–330.
   PubMed Web of Science ®Google Scholar
• Lo-Coco F, Hasan SK. Understanding the molecular pathogenesis of acute promyelocytic leukemia. Best Pract Res Clin Haematol 2014;27:3–9.
   PubMed Web of Science ®Google Scholar
• Pascual AM, Téllez N, Boscá I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Multiple Sclerosis 2009;15:1303–1310.
   PubMed Web of Science ®Google Scholar
• Ottone T, Cicconi L, Hasan SK, et al. Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia. Leuk Res 2012;36:474–478.
   PubMed Web of Science ®Google Scholar
• Smith SM, Le Beau MM, Huo D, et al. Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood 2003;102: 43–52.
   PubMed Web of Science ®Google Scholar
• Chen Y, Estrov Z, Pierce S, et al. Myeloid neoplasms after breast cancer: “therapy-related” not an independent poor prognostic factor. Leuk Lymphoma 2015:56:1012–1019.
   Google Scholar
• Braun T, Cereja S, Chevret S, et al. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): a prospective analysis by the French-Belgian-Swiss APL group. Cancer 2015:121:2393–2399.
   Google Scholar
• Lucena-Araujo AR, Kim HT, Jacomo RH, et al. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study. Ann Hematol 2014;93:2001–2010.
   PubMed Web of Science ®Google Scholar
• Beitinjaneh A, Jang S, Roukoz H, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res 2010;34:831–836.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Letendre L, Tefferi A, et al. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy. Eur J Haematol 2012;88:237–243.
   PubMed Web of Science ®Google Scholar
• Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012;120:1570–1580; quiz 1752.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010;115:5137–5146.
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Jin J, et al. Oral tetra-arsenic tetra-sulfide formula versus intravenous arsenic trioxide as first-line treatment of acute promyelocytic leukemia: a multicenter randomized controlled trial. J Clin Oncol 2013;31:4215–4221.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Petti MC, Lo-Coco F, et al. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Blood 2002;100: 3141–3146.
   PubMed Web of Science ®Google Scholar
• Avvisati G, Lo-Coco F, Paoloni FP, et al. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. Blood 2011;117:4716–4725.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Freedman DM, Ron E, et al. (eds). New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006. Accessed March 2015 from: http://seer.cancer.gov/archive/publications/mpmono/MPMonograph_complete.pdf
   Google Scholar
• Surveillance, Epidemiology, and End Results Program, Hematopoietic and Lymphoid Neoplasm Database. Accessed March 2015 from: http://seer.cancer.gov/seertools/hemelymph/51f6cf59e3e27c3994bd5414/
   Google Scholar
• Giri S, Shrestha R, Pathak R, et al. Racial differences in the overall survival of hairy cell leukemia in the united states: a population-based analysis of the surveillance, epidemiology, and end results database. Clin Lymphoma Myeloma Leuk 2015 Mar 24. [Epub ahead of print].
   Google Scholar
• Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. J Clin Oncol 2013;31:3869–3876.
   PubMed Web of Science ®Google Scholar
• Iacus SM, King G, Porro G. Causal inference without balance checking: coarsened exact matching. Political Analysis 2012;20:1–24.
   Web of Science ®Google Scholar
• Ho DE, Imai K, King G, et al. Matching as nonparametric preprocessing for reducing model dependence in parametric causal inference. Political Analysis 2007;15:199–236.
   Web of Science ®Google Scholar
• Stuart EA. Matching methods for causal inference: a review and a look forward. Statistical Sci 2010;25:1–21.
   PubMed Web of Science ®Google Scholar
• Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–1891.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248–1254.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf Å, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009;113:4179–4187.
   PubMed Web of Science ®Google Scholar
• Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011;25:1128–1134.
   PubMed Web of Science ®Google Scholar
• McClellan JS, Kohrt HE, Coutre S, et al. Treatment advances have not improved the early death rate in acute promyelocytic leukemia. Haematologica 2012;97:133–136.
   PubMed Web of Science ®Google Scholar
• Micol J-B, Raffoux E, Boissel N, et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the University Hospital Saint-Louis Between 2000 and 2010. Blood 2010;116 (Suppl): 1083 Abstract.
   PubMedGoogle Scholar
• Jillella AP, Kolhe RB, Natrajan K, et al. A successful model to decrease early deaths in acute promyelocytic leukemia (APL) through the use of a simplified algorithm and expert support. J Clin Oncol 2014;32 (Suppl):e18018.
   Google Scholar
• O’Donnell MR, Tallman MS, Abboud CN, et al. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia (Version I.2015). Accessed March 2015 from: http://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
   Google Scholar
• Rashidi A, Riley M, Goldin TA, et al. Delay in the administration of all-trans retinoic acid and its effects on early mortality in acute promyelocytic leukemia: final results of a multicentric study in the United States. Leuk Res 2014;38:1036–1040.
   PubMed Web of Science ®Google Scholar
• Dayyani F, Kantarjian H, O’Brien S, et al. Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy. Cancer 2011;117: 110–115.
   PubMed Web of Science ®Google Scholar
• Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011;118:1248–1254.
   PubMed Web of Science ®Google Scholar
• Chen Y, Kantarjian H, Wang H, et al. Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975–2008. Cancer 2012;118:5811–5818.
   PubMed Web of Science ®Google Scholar